Latest news with #Pharmaceuticals
Wall Street Journal
17 hours ago
- Business
- Wall Street Journal
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker. Shares of BioNTech, which closed Friday at $95.81, rose 14% to $109.54 in premarket trading Monday.
Yahoo
3 days ago
- Business
- Yahoo
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory
We came across a bullish thesis on Fulcrum Therapeutics, Inc. (FULC) on Stock Pursuit's Substack. In this article, we will summarize the bulls' thesis on FULC. Fulcrum Therapeutics, Inc. (FULC)'s share was trading at $6.44 as of 23rd May. FULC's trailing P/E was 312.50 according to Yahoo Finance. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Fulcrum Therapeutics (FULC) recently surged over 110% from around $3.30 to $7.00, reflecting growing optimism but also presenting a prime opportunity to take profits. The company's lead candidate, Pociredir (FTX-6058), is an oral small molecule in Phase 1b trials aimed at treating Sickle Cell Disease (SCD) by increasing fetal hemoglobin expression. While early data are encouraging, larger trials are needed to confirm efficacy and safety, especially following a prior clinical hold related to concerns over EED inhibitors. Analysts have raised their peak sales forecasts to roughly $600 million with a 50% probability of success, and Fulcrum's cash runway extends into 2027. Market dynamics favor Pociredir due to Pfizer's withdrawal of Oxbryta and slow adoption of gene therapies, creating scarcity value for new oral treatments. Beyond SCD, Fulcrum is developing programs for inherited aplastic anemias, with an Investigational New Drug application for Diamond-Blackfan anemia expected in late 2025. Despite this promise, history shows that small-cap pharma stocks can experience volatile reversals after big gains, so locking in profits while retaining a small position for potential upside on drug results seems prudent. The broader biotech sector, historically avoided by the author, has recently become more attractive due to technological advances and compelling net cash positions, as demonstrated by previous successes like Somalogic. Overall, Fulcrum represents a high-risk, high-reward opportunity in a niche with growing unmet medical needs, but caution and disciplined profit-taking remain essential given the sector's volatility. Fulcrum Therapeutics, Inc. (FULC) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held FULC at the end of the first quarter which was 23 in the previous quarter. While we acknowledge the risk and potential of FULC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than FULC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies
Rocket Pharmaceuticals halted a study of a gene-therapy drug for Danon disease because a patient had a "Serious Adverse Event" and later died. The patient suffered from complications related to a blood vessel leak. The news sent shares of Rocket Pharmaceuticals plunging to an all-time Pharmaceuticals (RCKT) shares plunged to an all-time low Tuesday when the drugmaker reported a patient taking its experimental treatment for Danon disease had a "Serious Adverse Event (SAE)" and later died, putting a halt to the research. The company explained that in a Phase 2 trial of its investigational gene therapy RP-A501, the patient experienced "clinical complications related to a capillary leak syndrome," and subsequently "passed away after an acute systemic infection." Rocket Pharmaceuticals said it is conducting a "comprehensive root cause analysis" that is currently focusing on "the recent introduction of a novel immune suppression agent to the pre-treatment regimen that had been implemented to mitigate complement activation observed in some patients." After the incident, Rocket Pharmaceuticals paused the study, and the Food and Drug Administration (FDA) placed a clinical hold on it. The company said it "is unable to provide guidance on the anticipated timing for completion of the Phase 2 trial." Shares of Rocket Pharmaceuticals lost 60% their value in Tuesday morning trading, and are down about 80% year-to-date. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-05-2025
- Business
- Yahoo
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
Pfizer faces several challenges, including looming patent expirations. However, the drugmaker's story is better than meets the eye. Pfizer's attractive valuation and ultra-high dividend yield make it a great pick right now. 10 stocks we like better than Pfizer › Most people like to buy products when prices are cheaper. That's why you'll probably see lots of car dealers, furniture stores, and retailers advertising special sales during the Memorial Day weekend. However, many investors are leery of buying a stock that has fallen sharply. Why? It's often because they're worried about getting caught in a value trap. But sometimes beaten-down stocks offer great bargains to forward-thinking investors. Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. I think, though, that this ultra-high-yield dividend stock is one to buy hand over fist. When a stock plunges as much as Pfizer has, there must be a reason behind the decline. Pfizer faces some real challenges that investors shouldn't ignore. The main factor causing the big pharma stock to initially sink back in late 2022 and 2023 was rapidly declining sales of its COVID-19 products. Waning worries about the pandemic, combined with increased vaccine skepticism, delivered a double-whammy to Pfizer. Product and pipeline setbacks have also hurt the drugmaker to some extent. Last year, Pfizer voluntarily withdrew its sickle cell disease therapy, Oxbryta, from the market because the benefits didn't outweigh the risks. More recently, the company discontinued development of experimental oral obesity drug danuglipron after a patient in a clinical trial had a drug-induced liver injury. Pfizer is also preparing for the patent expirations for several top-selling products. Cancer drug Inlyta loses patent exclusivity this year. Autoimmune disease drug Xeljanz and blood thinner Eliquis go off-patent next year. If all that isn't enough, Pfizer could be impacted by President Donald Trump's policies. The president has threatened tariffs on pharmaceutical imports. His administration also plans to implement international reference pricing, also known as most-favored nation (MFN) pricing. This would tie the prices paid for drugs in the U.S. to the lowest price paid by other developed countries. You might think Wall Street would scream for investors to avoid Pfizer like the plague with all that bad news. However, that's not the case. Eight of the 25 analysts surveyed by LSEG in May rate Pfizer as a buy or strong buy. All of the others surveyed, except for one outlier, recommend holding the stock. The average 12-month price target for Pfizer reflects an upside potential of 28%. Why is there a significant level of optimism on Wall Street about this beaten-down pharma stock? For one thing, Pfizer isn't nearly as reliant on COVID-19 product sales as it was during the peak of the pandemic. In the first quarter of 2025, COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid made up less than 7.7% of total revenue. Pfizer hopes to delay the loss of exclusivity for several drugs by securing patent term extensions. More importantly, the company has multiple rising stars that it thinks can more than offset the sales declines from the drugs that lose exclusivity over the next few years. Look for business development deals to help further boost growth. Pfizer recently announced it's licensing a promising cancer drug being developed by Chinese drugmaker 3SBio. CEO Albert Bourla hinted on the company's Q1 earnings call that Pfizer could pursue partnerships or acquisitions to bolster its pipeline and specifically mentioned obesity. The Trump administration's policies create uncertainty for Pfizer. However, President Trump himself assured pharmaceutical industry leaders they would have plenty of time to adjust operations before steep pharmaceutical tariffs go into effect. Also, global law firm Reed Smith concluded after reviewing the president's executive order about MFN drug pricing: [A]bsent congressional legislation authorizing the imposition of MFN prices -- which the pharmaceutical industry and many in Congress still oppose -- it remains highly questionable whether the Trump Administration will be able to impose any reduction of pharmaceutical prices to match those in other countries. I don't think that Pfizer is a stock to buy hand over fist just because its story is better than meets the eye (although this is good news). Instead, I have two key reasons for liking Pfizer right now. First, the price is right. Pfizer's shares trade at a little over 8 times forward earnings. That cheap multiple might be justified if the company had no growth prospects, but that's not the case. Pfizer's price-to-earnings-to-growth (PEG) ratio, based on five-year earnings growth projections, is a low 0.6. This indicates the stock's valuation is very attractive relative to its growth prospects. Second, Pfizer's forward dividend yield stands at 7.47%. At first glance, the drugmaker's dividend payout ratio of 122.5% might seem concerning. However, Pfizer has sufficient free cash flow to fund its dividend at the current level. It also anticipates cost savings of $7.2 billion by 2027 that should provide more financial flexibility. The bottom line is that Pfizer should be in a pretty good position to navigate its challenges. The stock is dirt cheap. Its ultra-high dividend yield provides a nice platform from which to deliver solid total returns. All in all, I think Pfizer meets the bar as a stock to buy hand over fist. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $640,662!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $814,127!* Now, it's worth noting Stock Advisor's total average return is 963% — a market-crushing outperformance compared to 168% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-05-2025
- Business
- Yahoo
The AFT Pharmaceuticals Limited (NZSE:AFT) Annual Results Are Out And Analysts Have Published New Forecasts
AFT Pharmaceuticals Limited (NZSE:AFT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Results look to have been somewhat negative - revenue fell 3.2% short of analyst estimates at NZ$208m, and statutory earnings of NZ$0.11 per share missed forecasts by 3.3%. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Taking into account the latest results, the current consensus from AFT Pharmaceuticals' dual analysts is for revenues of NZ$245.5m in 2026. This would reflect a meaningful 18% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to jump 36% to NZ$0.16. Before this earnings report, the analysts had been forecasting revenues of NZ$255.9m and earnings per share (EPS) of NZ$0.18 in 2026. From this we can that sentiment has definitely become more bearish after the latest results, leading to lower revenue forecasts and a real cut to earnings per share estimates. Check out our latest analysis for AFT Pharmaceuticals The analysts made no major changes to their price target of NZ$3.70, suggesting the downgrades are not expected to have a long-term impact on AFT Pharmaceuticals' valuation. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of AFT Pharmaceuticals'historical trends, as the 18% annualised revenue growth to the end of 2026 is roughly in line with the 16% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 30% annually. So although AFT Pharmaceuticals is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry. The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for AFT Pharmaceuticals. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. The consensus price target held steady at NZ$3.70, with the latest estimates not enough to have an impact on their price targets. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for AFT Pharmaceuticals going out as far as 2028, and you can see them free on our platform here. You can also view our analysis of AFT Pharmaceuticals' balance sheet, and whether we think AFT Pharmaceuticals is carrying too much debt, for free on our platform here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
